Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors

US10800826B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Ambryx, Inc. · US

Inventors

• Paul E. Carrington · San Mateo, US
• Grigori P. Ermakov · Santa Clara, US
• Robert M. Garbaccio · Lansdale, US
• Wolfgang Seghezzi · Mountain View, US
• Elisabetta Bianchi · Pomezia, IT
• Federica Orvieto · Roma, IT
• Dennis Gately · Philadelphia, US
• Nick Knudsen · San Diego, US
• Anthony Manibusan · San Diego, US

Key dates

• Filing date: Oct 4, 2016
• Grant date: Oct 13, 2020
• Expiry date: Oct 23, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.